<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of Cystoisospora (Isospora) infections
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of Cystoisospora (Isospora) infections
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of Cystoisospora (Isospora) infections
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karin Leder, MBBS, FRACP, PhD, MPH, DTMH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Weller, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H31776247">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Cystoisospora belli
         </em>
         (formerly known as
         <em>
          Isospora belli
         </em>
         ) is an opportunistic protozoan that in immunocompetent patients can cause self-limited watery diarrhea. However, in immunocompromised patients, such as those with the acquired immune deficiency syndrome (AIDS), it can result in severe debilitating chronic diarrhea with wasting.
        </p>
        <p>
         The clinical management of patients with
         <em>
          Cystoisospora
         </em>
         infection will be discussed here. The epidemiology, clinical manifestations, and diagnosis of
         <em>
          Cystoisospora
         </em>
         infection are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5725.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Cystoisospora (Isospora) infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1439256641">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with
         <em>
          Cystoisospora
         </em>
         involves supportive treatment for the dehydration and malnutrition associated with a severe diarrheal illness. For certain patients, especially immunocompromised hosts, antibiotic therapy against the pathogen is also administered. There are special treatment considerations for individuals with HIV, such as early initiation of potent antiretroviral therapy and secondary prophylaxis. (See
         <a class="local">
          'Secondary prophylaxis'
         </a>
         below and
         <a class="local">
          'Antiretroviral therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1439256647">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
        </p>
        <p class="headingAnchor" id="H31776254">
         <span class="h2">
          Fluid and electrolyte support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with
         <em>
          Cystoisospora
         </em>
         infection may have evidence of severe volume depletion and electrolyte abnormalities, such as hypokalemia, hypomagnesemia, and bicarbonate wasting. Aggressive fluid resuscitation is critical with intravenous crystalloid, as well as supplementation of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         . Cardiac monitoring may be necessary for patients with severe electrolyte imbalances. (See
         <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">
          "Maintenance and replacement fluid therapy in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31776261">
         <span class="h2">
          Nutritional support
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to address nutritional needs with parenteral nutritional support (where feasible) followed by enteral or oral feeding as soon as the patient’s clinical symptoms improve. Immunocompromised patients (eg, patients with acquired immune deficiency syndrome [AIDS]) who have chronic diarrhea from enteric pathogens often have malabsorption of fats and vitamins, which can lead to elevated prothrombin and low serum albumin levels. Malnutrition can also lead to significant thymic gland atrophy that can affect T cell mediated immune responses [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31776268">
         <span class="h1">
          ANTIMICROBIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H387916375">
         <span class="h2">
          Approach to treatment
         </span>
        </p>
        <p class="headingAnchor" id="H97354156">
         <span class="h3">
          Immunocompetent
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the immunocompetent host, symptoms of
         <em>
          Cystoisospora
         </em>
         infection are usually self-limited. We would administer antimicrobial therapy to such patients only if symptoms did not start to resolve spontaneously (eg, after five to seven days, depending upon severity).
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX), one double-strength tablet (160 mg TMP component) orally twice daily for 7 to 10 days, is usually sufficient for eradication of infection [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In patients allergic to TMP-SMX, we prefer
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (500 mg twice daily for 7 to 10 days) based principally upon data derived from the treatment of immunocompromised hosts. Other alternatives include
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">
          nitazoxanide
         </a>
         . (See
         <a class="local">
          'Alternative agents'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H97354162">
         <span class="h3">
          Immunocompromised
         </span>
         <span class="headingEndMark">
          —
         </span>
         We would treat all symptomatic immunocompromised patients with antimicrobial therapy. Most published experience is in individuals with the AIDS [
         <a href="#rid3">
          3
         </a>
         ]. Limited case reports describe treatment in other immunocompromised hosts including transplant recipients and patients with a malignancy [
         <a href="#rid4">
          4-9
         </a>
         ].
        </p>
        <p>
         For immunocompromised patients, we administer initial therapy with oral or intravenous TMP-SMX (160 mg TMP component) twice daily for 7 to 10 days [
         <a href="#rid3">
          3
         </a>
         ]. Some guidelines recommend initiation of TMP-SMX at a higher dose of four times per day [
         <a href="#rid10">
          10
         </a>
         ], although no comparative studies have been performed. Our approach is generally to start with a twice-daily regimen and increase the daily dose if symptoms worsen or persist. A longer duration of therapy of up to three to four weeks may be needed depending on clinical response. Most patients with mild or moderate disease can be started on oral therapy, whereas those with severe, cholera-like diarrhea and/or malabsorption require intravenous therapy. In patients with severe immunosuppression (eg, patients with HIV and CD4 cell counts &lt;200 cells/microL, solid organ transplant recipients, other immunocompromised individuals with recurrent symptoms), the initial course of antibiotics may be followed by suppressive doses (ie, secondary prophylaxis) because symptoms can recur once treatment has been discontinued [
         <a href="#rid3">
          3,11-13
         </a>
         ]. (See
         <a class="local">
          'Secondary prophylaxis'
         </a>
         below.)
        </p>
        <p>
         This approach is based upon the following two clinical studies in Haiti that enrolled small numbers of patients with HIV [
         <a href="#rid11">
          11,14
         </a>
         ]. Symptomatic improvement was usually dramatic with resolution of symptoms within two days of treatment initiation [
         <a href="#rid11">
          11
         </a>
         ]. Both of these trials were conducted before the era of potent antiretroviral therapy and the CD4 cell counts of the enrolled patients were not specified [
         <a href="#rid11">
          11,14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, 20 patients with a history of chronic diarrhea and
         <em>
          Cystoisospora
         </em>
         infection were treated with TMP-SMX (160 mg TMP component) four times daily for 10 days, followed by twice daily for three weeks [
         <a href="#rid11">
          11
         </a>
         ]. One patient had to stop therapy because of a pruritic drug rash. Approximately half of the patients had a recurrence of symptomatic infection within a mean of eight weeks of treatment discontinuation; all responded to a repeat course of TMP-SMX within approximately two days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent trial compared the efficacy of TMP-SMX (160 mg TMP component) twice daily with
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (500 mg) twice daily for the treatment and prevention of chronic diarrhea in 42 patients with HIV, of whom approximately half had infection with
         <em>
          Cystoisospora
         </em>
         [
         <a href="#rid14">
          14
         </a>
         ]. At the end of treatment, the proportion of patients with symptom resolution and microbiologic cure (100 and 83 percent, respectively) was superior in the TMP-SMX arm compared with the ciprofloxacin arm (90 and 75 percent, respectively). Patients who had evidence of persistent
         <em>
          Cystoisospora
         </em>
         infection after initial treatment with ciprofloxacin had eradication of their infection after being switched to TMP-SMX. The duration of diarrhea was also shorter in patients assigned to the TMP-SMX arm (2 versus 4.2 days).
        </p>
        <p>
        </p>
        <p>
         The management of patients who cannot take TMP-SMX, as well as those who continue to have diarrhea 48 hours after starting treatment, is described below. (See
         <a class="local">
          'Alternative agents'
         </a>
         below and
         <a class="local">
          'Management of treatment failure'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H31776282">
         <span class="h3">
          Alternative agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although clinical data are limited, alternative agents are available for patients who cannot tolerate TMP-SMX. We typically administer
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (500 mg twice daily) to such patients. As noted in the small clinical trial above, ciprofloxacin was inferior to TMP-SMX, but did lead to symptom resolution and microbiologic cure in approximately three-quarters of the patients [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Other less desirable options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          Pyrimethamine
         </a>
         – In one case report, two patients with
         <em>
          Cystoisospora
         </em>
         infection and sulfonamide allergies were treated with pyrimethamine (75 mg/day) for three to four weeks followed by suppressive maintenance therapy (25 mg/day) with good clinical outcomes [
         <a href="#rid15">
          15
         </a>
         ].
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          Leucovorin
         </a>
         (5 to 10 mg/day) should be coadministered to prevent the hematologic toxicity associated with the use of pyrimethamine [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">
          Nitazoxanide
         </a>
         – Nitazoxanide has in vitro activity against
         <em>
          Cystoisospora
         </em>
         [
         <a href="#rid16">
          16
         </a>
         ]. Although some clinical data suggest that nitazoxanide may be effective against
         <em>
          Cystoisospora
         </em>
         and other enteric pathogens (eg,
         <em>
          Cryptosporidium
         </em>
         ,
         <em>
          Giardia
         </em>
         ), data are sparse [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unsubstantiated or mixed data are available for
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          albendazole
         </a>
         and the macrolides roxithromycin and
         <a class="drug drug_general" data-topicid="10092" href="/z/d/drug information/10092.html" rel="external">
          spiramycin
         </a>
         [
         <a href="#rid3">
          3,19-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Limited data suggest that drugs such as
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         , quinacrine,
         <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">
          paromomycin
         </a>
         , and furazolidone are ineffective [
         <a href="#rid3">
          3
         </a>
         ]. Additionally,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         have
         <strong>
          not
         </strong>
         been shown to be effective for the treatment of
         <em>
          Cystoisospora
         </em>
         [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31776310">
         <span class="h2">
          Management of treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         If symptoms worsen or persist after two to three days of therapy, the possibility of medication noncompliance, malabsorption, and/or concurrent infections should be considered. Drug resistant strains of
         <em>
          Cystoisospora
         </em>
         have not been reported.
        </p>
        <p>
         If there are no alternative reasons for treatment failure, our approach, which is consistent with treatment guidelines for individuals with HIV [
         <a href="#rid3">
          3
         </a>
         ], is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If malabsorption of drug is a concern, TMP-SMX should be given intravenously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with worsening symptoms on a twice-daily regimen, the dosing frequency can be increased to four times a day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose symptoms persist after 7 to 10 days, the treatment duration can be extended to 3 to 4 weeks.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31776317">
         <span class="h2">
          Secondary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of secondary prophylaxis is to decrease the risk of relapse and/or reinfection. Our approach is consistent with guideline recommendations [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer secondary prophylaxis with TMP-SMX, one double-strength tablet (160 mg TMP component) orally three times per week, to patients with HIV and a CD4 cell count &lt;200 cells/microL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternative regimens, for which there are some data for efficacy, include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         TMP-SMX, one double-strength tablet orally on a daily basis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         TMP-SMX, two double-strength tablets orally three times a week
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          Pyrimethamine
         </a>
         (25 mg) plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         (5 to 10 mg) orally on a daily basis (if sulfa-intolerant)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         (500 mg) orally three times a week (if sulfa-intolerant, but considered second-line alternative)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of secondary prophylaxis against reinfection or relapse is supported by a trial conducted among 32 patients with AIDS and chronic
         <em>
          Cystoisospora
         </em>
         infection [
         <a href="#rid12">
          12
         </a>
         ]. Patients were initially treated with 10 days of TMP-SMX. After clinical resolution of symptoms, patients were randomly assigned to receive TMP-SMX (160 mg TMP component) orally three times a week,
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         (25 mg) plus sulfadoxine (500 mg) orally once a week, or placebo. Half of the patients taking placebo had a recurrence of
         <em>
          Cystoisospora
         </em>
         -related diarrhea within a mean of 1.6 months after discontinuation of therapy. Among the 22 patients in the intervention arms, there was no recurrence of diarrhea, and only one patient in the TMP-SMX arm had a microbiologic relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of secondary prophylaxis for immunocompromised hosts without HIV is less clear given the lack of data in such patients. We would consider administering secondary prophylaxis to patients who have undergone hematopoietic stem cell or solid organ transplantation, and/or immunocompromised hosts with relapsed
         <em>
          Cystoisospora
         </em>
         infection. This decision is based upon a variety of factors including severity of symptoms, prognosis of the patient’s underlying disease, and/or drug tolerability/interactions.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31776331">
         <span class="h3">
          Duration of prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of secondary prophylaxis is unknown. It may be possible to discontinue therapy for
         <em>
          Cystoisospora
         </em>
         in patients with HIV who have had immune reconstitution on potent antiretroviral therapy (ART). However, there have been case reports of recurrent Cystoisosporiasis in such patients [
         <a href="#rid23">
          23
         </a>
         ]. Despite this, we discontinue secondary prophylaxis in patients who have a sustained increase in their CD4 cell count to levels &gt;200 cells/microL for at least six months. These individuals should be closely monitored for recurrent symptoms.
        </p>
        <p class="headingAnchor" id="H26461424">
         <span class="h1">
          ANTIRETROVIRAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with HIV, treatment of their underlying immunosuppression with antiretroviral therapy (ART) is essential for treatment success:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients already receiving suppressive ART, we continue their current regimen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient is not being administered ART, ART should be initiated concurrently with antibiotic treatment [
         <a href="#rid3">
          3
         </a>
         ]. Among those requiring initial intravenous antimicrobial therapy, ART should begin as soon as the patient can tolerate oral treatment. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients with
         <em>
          Cystoisospora
         </em>
         infection, immune recovery secondary to ART can lead to fewer relapses of disease. Unlike other opportunistic infections where there are concerns for the development of an immune reconstitution inflammatory syndrome (IRIS), no cases have been reported in the setting of
         <em>
          Cystoisospora
         </em>
         infection [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31776338">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of prevention for
         <em>
          Cystoisospora
         </em>
         infection is avoiding exposure to contaminated food or water in endemic areas. We do
         <strong>
          not
         </strong>
         initiate preventive antibiotics for travelers, regardless of their immune status [
         <a href="#rid3">
          3
         </a>
         ]
        </p>
        <p>
         However, individuals with HIV and CD4 cell counts &lt;200 cells/microL should be encouraged to continue on
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) if they are receiving this agent for the prevention of other opportunistic infections. Observational data of patients with HIV in sub-Saharan Africa suggest that the incidence of
         <em>
          Cystoisospora
         </em>
         infections may be reduced in those who are receiving TMP-SMX prophylaxis against
         <em>
          Pneumocystis
         </em>
         infection [
         <a href="#rid3">
          3,24-26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">
          "Overview of prevention of opportunistic infections in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H368731244">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109942.html" rel="external">
          "Society guideline links: Acute diarrhea in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31776345">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fluid and electrolyte support
         </strong>
         –
         <strong>
         </strong>
         Patients with
         <em>
          Cystoisospora
         </em>
         infection may have evidence of severe volume depletion and electrolyte abnormalities, such as hypokalemia, hypomagnesemia, and bicarbonate wasting. Aggressive fluid resuscitation is critical with intravenous crystalloid and supplements of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         . (See
         <a class="local">
          'Fluid and electrolyte support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nutritional support
         </strong>
         –
         <strong>
         </strong>
         Patients with chronic diarrhea may require nutritional support resulting from malabsorption of fats and vitamins, which can lead to elevated prothrombin levels and low serum albumin. (See
         <a class="local">
          'Nutritional support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimicrobial therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In the immunocompetent host, symptoms
         <em>
          of Cystoisospora
         </em>
         infection are usually self-limited. Thus, treatment is usually not required. (See
         <a class="local">
          'Immunocompetent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In the immunocompromised patient (eg, patients with HIV and a CD4 cell count &lt;200), untreated
         <em>
          Cystoisospora
         </em>
         can lead to debilitating chronic diarrhea and weight loss. Antimicrobial treatment, followed by secondary prophylaxis for certain patients, is the mainstay of clinical management. (See
         <a class="local">
          'Immunocompromised'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preferred treatment
         </strong>
         –
         <strong>
         </strong>
         For all patients requiring antimicrobial therapy, we prefer
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) (160 mg TMP component) twice daily for 7 to 10 days. The frequency of dosing should be increased to four times a day among those patients who continue to have diarrhea 48 hours after starting treatment. (See
         <a class="local">
          'Approach to treatment'
         </a>
         above and
         <a class="local">
          'Management of treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative agents
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">
          nitazoxanide
         </a>
         are alternative agents for patients who are intolerant of TMP-SMX. (See
         <a class="local">
          'Alternative agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Secondary prophylaxis
         </strong>
         –
         <strong>
         </strong>
         For individuals with HIV and a CD4 cell count &lt;200 cells/microL, as well as certain other immunocompromised hosts, we administer secondary prophylaxis with TMP-SMX, one double-strength tablet (160 mg TMP component) orally three times a week. We discontinue secondary prophylaxis for patients with HIV infection receiving antiretroviral therapy (ART) if they have a sustained increase in their CD4 cell count to levels &gt;200 cells/microL for at least six months. (See
         <a class="local">
          'Secondary prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ART initiation
         </strong>
         –
         <strong>
         </strong>
         In patients with HIV, ART should be started as soon as an individual is able to tolerate oral medications. Immune recovery secondary to ART can lead to fewer relapses of disease. (See
         <a class="local">
          'Antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         –
         <strong>
         </strong>
         To prevent infection with
         <em>
          Cystoisospora
         </em>
         , individuals should avoid exposure to contaminated food or water in endemic areas. We do
         <strong>
          not
         </strong>
         recommend preventative antibiotics for travelers, regardless of their immune status. However, individuals with HIV and CD4 cell counts &lt;200 cells/microL should be encouraged to continue on TMP-SMX if they are receiving this agent for the prevention of other opportunistic infections. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Savino W, Dardenne M. Nutritional imbalances and infections affect the thymus: consequences on T-cell-mediated immune responses. Proc Nutr Soc 2010; 69:636.
          </a>
         </li>
         <li class="breakAll">
          Drugs for Parasitic Infections. The Medical Letter on Drugs and Therapeutics 2013.
         </li>
         <li class="breakAll">
          Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association, and the Infectious Disease Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cystoisosporiasis?view=full (Accessed on October 19, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ud Din N, Torka P, Hutchison RE, et al. Severe Isospora (Cystoisospora) belli Diarrhea Preceding the Diagnosis of Human T-Cell-Leukemia-Virus-1-Associated T-Cell Lymphoma. Case Rep Infect Dis 2012; 2012:640104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marathe A, Parikh K. Severe diarrhoea due to Cystoisospora belli in renal transplant patient on immunosuppressive drugs. Indian J Med Microbiol 2013; 31:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usluca S, Inceboz T, Unek T, Aksoy U. Isospora belli in a patient with liver transplantation. Turkiye Parazitol Derg 2012; 36:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marques J, Menezes M, Mendes F, et al. A rare diarrheic parasite in a kidney transplant patient: Cystoisospora belli. Transpl Infect Dis 2020; 22:e13237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubey JP, Almeria S. Cystoisospora belli infections in humans: the past 100 years. Parasitology 2019; 146:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Özmen-Çapın BB, Gürsoy G, Tortop S, et al. Cystoisospora belli infection in a renal transplant recipient: a case report and review of literature. J Infect Dev Ctries 2021; 15:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagrange-Xélot M, Porcher R, Sarfati C, et al. Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med 2008; 9:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000; 132:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss LM, Perlman DC, Sherman J, et al. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med 1988; 109:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doumbo O, Rossignol JF, Pichard E, et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 1997; 56:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dionisio D, Sterrantino G, Meli M, et al. Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS. AIDS 1996; 10:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaska JA, Tietze KJ, Cosgrove EM. Unsuccessful treatment of enteritis due to Isospora belli with spiramycin: a case report. J Infect Dis 1985; 152:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musey KL, Chidiac C, Beaucaire G, et al. Effectiveness of roxithromycin for treating Isospora belli infection. J Infect Dis 1988; 158:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trier JS, Moxey PC, Schimmel EM, Robles E. Chronic intestinal coccidiosis in man: intestinal morphology and response to treatment. Gastroenterology 1974; 66:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyles TH, Black J, Meintjes G, Mendelson M. Failure to eradicate Isospora belli diarrhoea despite immune reconstitution in adults with HIV--a case series. PLoS One 2012; 7:e42844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorvillo FJ, Lieb LE, Seidel J, et al. Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County. Am J Trop Med Hyg 1995; 53:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guiguet M, Furco A, Tattevin P, et al. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med 2007; 8:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16969 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20860857" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Nutritional imbalances and infections affect the thymus: consequences on T-cell-mediated immune responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20860857" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Nutritional imbalances and infections affect the thymus: consequences on T-cell-mediated immune responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20860857" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Nutritional imbalances and infections affect the thymus: consequences on T-cell-mediated immune responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22953083" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Severe Isospora (Cystoisospora) belli Diarrhea Preceding the Diagnosis of Human T-Cell-Leukemia-Virus-1-Associated T-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23867679" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Severe diarrhoea due to Cystoisospora belli in renal transplant patient on immunosuppressive drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23339948" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Isospora belli in a patient with liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31884694" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A rare diarrheic parasite in a kidney transplant patient: Cystoisospora belli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31303182" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Cystoisospora belli infections in humans: the past 100 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33956664" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cystoisospora belli infection in a renal transplant recipient: a case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31145496" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3487730" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2927483" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18257775" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10836915" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3261956" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Isospora belli infection: treatment with pyrimethamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717338" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nitazoxanide (Alinia)--a new anti-protozoal agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230795" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15791519" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nitazoxanide: a new thiazolide antiparasitic agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8883600" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4067332" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Unsuccessful treatment of enteritis due to Isospora belli with spiramycin: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3411149" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effectiveness of roxithromycin for treating Isospora belli infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4826994" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Chronic intestinal coccidiosis in man: intestinal morphology and response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22880120" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Failure to eradicate Isospora belli diarrhoea despite immune reconstitution in adults with HIV--a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8561272" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17352769" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10232311" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
